This is a news story, published by Investor's Business Daily, that relates primarily to Halozyme Therapeutics news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Investor's Business Daily, you can click here:
more news from Investor's Business DailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Biotech stock Halozyme Therapeutics. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest biopharmaceutical company news, Pharma Industry News news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Biotech StocksInvestor's Business Daily
•Health
Health
59% Informative
Halozyme Therapeutics has held up relatively well amid recent market volatility.
Shares made progress this week , finding support at their 200-day line in a time when many stocks are below this level.
Halozyme is a leading biopharmaceutical company that developed a specialized drug delivery technology.
VR Score
48
Informative language
44
Neutral language
9
Article tone
formal
Language
English
Language complexity
50
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links
